INT80862

Context Info Confidence 0.57 First Reported 1999 Last Reported 2009 Negated 0 Speculated 0 Reported most in Abstract Documents 5 Total Number 5 Disease Relevance 1.66 Pain Relevance 2.13

small molecule metabolic process (CYP3A5) oxidoreductase activity (CYP3A5) endoplasmic reticulum (CYP3A5)

Anatomy Link Frequency liver 1 CYP3A5 (Homo sapiens)

Pain Link Frequency Relevance Heat vincristine 12 99.38 fluoxetine 8 97.96 antidepressant 6 96.40 sSRI 2 94.68 Dopamine 6 92.68 imagery 2 86.28 Nucleus accumbens 3 83.52 abdominal pain 2 83.20 methotrexate 2 80.00 Eae 3 79.08

Disease Link Frequency Relevance Heat Toxicity 2 98.24 Ileus 2 86.56 Intestinal Pseudo-obstruction 4 85.04 Constipation 3 84.36 Pressure Volume 2 Under Development 12 83.80 Abdominal Pain 2 83.20 Epstein-barr Virus 2 76.36 Attention Deficit Hyperactivity Disorder 1 75.00 Infection 2 70.48 Acquired Immune Deficiency Syndrome Or Hiv Infection 2 70.08

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Further, the results indicate that fluoxetine potentiates the effects of amphetamine by decreasing the metabolism of amphetamine, probably through inhibition of cytochrome P450 isozymes.

Negative_regulation (inhibition) of cytochrome P450 associated with fluoxetine

1) Confidence 0.57 Published 1999 Journal Psychopharmacology (Berl.) Section Abstract Doc Link 10090650 Disease Relevance 0.07 Pain Relevance 1.06

HPP(+) formation followed Michaelis-Menten kinetics in microsomes, recombinant CYP3A4, and CYP3A5 with K(m) values of 24.4 +/- 8.9 microM, 18.3 +/- 4.9 microM, and 200.2 +/- 47.6 microM, respectively, and V(max) values of 157.6 +/- 13.2 pmol/min/mg of protein, 10.4 +/- 0.6 pmol/min/pmol P450, and 5.16 +/- 0.6 pmol/min/pmol P450, respectively.

Negative_regulation (followed) of CYP3A5

2) Confidence 0.43 Published 2003 Journal Drug Metab. Dispos. Section Abstract Doc Link 12584149 Disease Relevance 0 Pain Relevance 0.18

It is both a substrate and potent inhibitor of the liver cytochrome P450 isozyme CYP3A4.

Negative_regulation (inhibitor) of cytochrome P450 in liver

3) Confidence 0.42 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2504060 Disease Relevance 0.14 Pain Relevance 0.03

Ritonavir is a potent CYP3A5 isoenzyme and P-gp inhibitor.

Negative_regulation (inhibitor) of CYP3A5

4) Confidence 0.40 Published 2009 Journal Pharm World Sci Section Abstract Doc Link 19757141 Disease Relevance 0.71 Pain Relevance 0.43

Vincristine is transported by P-gp and is metabolized via CYP3A5.

Negative_regulation (metabolized) of CYP3A5 associated with vincristine

5) Confidence 0.40 Published 2009 Journal Pharm World Sci Section Abstract Doc Link 19757141 Disease Relevance 0.73 Pain Relevance 0.43

General Comments

This test has worked.